Compare · KIN vs UROV
KIN vs UROV
Side-by-side comparison of Kindred Biosciences, Inc. (KIN) and Urovant Sciences Ltd. (UROV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KIN and UROV operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- KIN carries a market cap of $420.5M.
- Company
- Kindred Biosciences, Inc.
- Urovant Sciences Ltd.
- Price
- $9.25+0.00%
- -
- Market cap
- $420.5M
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2013
- 2018
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 0
Kindred Biosciences, Inc.
Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, engages in developing therapies for pets. Its product pipeline focuses on biologics for a range of indications primarily in dogs and cats. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats; and Zimeta, a dipyrone injection for the control of fever in horses. It also develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-032, a monoclonal antibody targeting interleukin-4 (IL-4) receptor for the treatment of atopic dermatitis in dogs; KIND-025 a canine fusion protein targeting IL-4 and IL-13 for atopic dermatitis in dogs; KIND-030, a monoclonal antibody targeting canine parvovirus for the prophylactic indication in dogs; KIND-509, an antibody for canine inflammatory bowel disease in dogs; KIND-510a, a long-acting feline recombinant erythropoietin being developed for the management of non-regenerative anemia in cats; and KIND-511, an anti-tumor necrosis factor treatment for newborn foals. The company was incorporated in 2012 and is headquartered in Burlingame, California.
Latest KIN
- TCW Special Purpose Acquisition Corp. Appoints Nanxi Liu to Board of Directors
- SEC Form SC 13G/A filed by Kindred Biosciences, Inc. (Amendment)
- SEC Form 4 filed by Park West Asset Management Llc
- SEC Form 15-12B filed by Kindred Biosciences, Inc.
- SEC Form EFFECT filed by Kindred Biosciences, Inc.
- SEC Form SC 13D/A filed by Kindred Biosciences, Inc. (Amendment)
- SEC Form 4: Chin Richard returned $15,884,757 worth of Common Stock to the company (1,717,271 units at $9.25), closing all direct ownership in the company
- SEC Form 4: Wee Wendy returned $727,170 worth of Common Stock to the company (78,613 units at $9.25), closing all direct ownership in the company
- SEC Form 4: Bevers Denise returned $1,348,974 worth of Common Stock to the company (145,835 units at $9.25), closing all direct ownership in the company
- SEC Form 4: Zhan Hangjun returned $594,830 worth of Common Stock to the company (64,306 units at $9.25), closing all direct ownership in the company
Latest UROV
- Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902
- Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® (vibegron) 75 mg
- Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients
- SEC Form 15-12B filed by Urovant Sciences Ltd.
- SEC Form EFFECT filed by Urovant Sciences Ltd.
- SEC Form 4: E. Bryan Smith disposed to the issuer $0 worth of Common Shares (124,447 units at $0.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: Sef Kurstjens disposed to the issuer $0 worth of Common Shares (21,480 units at $0.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: M. James Hindman disposed to the issuer $0 worth of Common Shares (9,000 units at $0.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: Cornelia Haag-Molkenteller disposed to the issuer $0 worth of Common Shares (141,348 units at $0.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: Ajay Bansal disposed to the issuer $0 worth of Common Shares (140,098 units at $0.00), decreasing direct ownership by 100% to 0 units